Skip to main content
SHPMY logo

Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) Stock Price & Analysis

Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) — price $6.87 (0.00%), as of the Nov 20, 2026 trading session; market cap $5.09B.

Educational signal · not a buy or sell recommendation · How to read this

$6.87 $0.00 (0.00%) Market Cap $5.09B

Shanghai Pharmaceuticals Holding Co., Ltd · SHPMY

Shanghai Pharmaceuticals Holding Co., Ltd. is a leading Chinese pharmaceutical company involved in the research, development, manufacturing, distribution, and retail of pharmaceutical and healthcare products. With a broad portfolio and extensive distribution network, the company plays a significant role in China's healthcare industry.

Price as of Nov 20, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • GRDN · Guardian Pharmacy Services, Inc. · 96 /100
  • HSIC · Henry Schein, Inc. · 73 /100
  • PBH · Prestige Consumer Healthcare Inc. · 63 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$6.87
Change on the day0.00%
52-week range$6.41 – $8.23
Market capitalisation$5.09B—
Price / earnings (trailing)11.96
Shares traded on the day1

Price & events

Other perspectives

Council score for Shanghai Pharmaceuticals Holding Co. (SHPMY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

2 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Weak
ROE Neutral
Gross Margin Weak

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Shanghai Pharmaceuticals Holding Co. (SHPMY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) is the company analyzed here. It employs 49,608 people and is led by Qiuhua Yang. In Q3 FY2026 it reported revenue of CN¥75.49B and net income of CN¥1.08B. The market values it at $5.09B.

2 · Latest results

What do the latest results show for Shanghai Pharmaceuticals Holding Co. (SHPMY)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of CN¥75.49B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026CN¥75.49BCN¥1.08BCN¥1.50 (diluted)
Q2 FY2026CN¥72.00BCN¥2.08BCN¥2.80 (diluted)
Q1 FY2026CN¥75.26BCN¥1.42BCN¥1.90 (diluted)
Q4 FY2025CN¥68.51BCN¥581MCN¥0.75 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Shanghai Pharmaceuticals Holding Co. (SHPMY)?

Short answer · as of

The distress and quality screens read Altman Z 2.00 · Piotroski F 7. Trailing ratios: ROE 6.6% · ROA 2.1% · current ratio 1.35 · earnings yield 8.4% · free-cash-flow yield 15.7%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SHPMY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SHPMY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Shanghai Pharmaceuticals Holding Co. Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the SHPMY research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is SHPMY a good stock to buy?

Stock Expert AI does not rate SHPMY buy, sell or hold. Shanghai Pharmaceuticals Holding Co., Ltd has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SHPMY stock price today?

The last price recorded for Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for SHPMY?

The main risks for Shanghai Pharmaceuticals Holding Co., Ltd. include regulatory changes and pricing pressures in the Chinese pharmaceutical market, which can impact profitability. Currency fluctuations can also affect the value of its ADR for U.S. investors. Increasing competition from both domestic and international players poses a threat to its market share.

What are the key factors to evaluate for SHPMY?

Evaluate SHPMY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies and acquiring smaller players can expand its product portfolio and market reach. Not financial advice.

How frequently does SHPMY data refresh on this page?

SHPMY's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SHPMY's recent stock price performance?

Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated business model covering R&D, manufacturing, distribution, and retail. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SHPMY overvalued or undervalued right now?

The trailing P/E of Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research SHPMY before investing?

Before investing in Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.